Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Clene Inc.
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
February 13, 2023
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
January 11, 2023
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
December 27, 2022
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
December 12, 2022
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
November 28, 2022
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
November 07, 2022
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
October 31, 2022
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
October 03, 2022
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
September 30, 2022
From
Clene Inc.
Via
GlobeNewswire
Tickers
CLNN
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.